Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$119.79 USD
+1.35 (1.14%)
Updated Oct 31, 2025 03:59 PM ET
After-Market: $119.74 -0.05 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Fundamental Charts
About Market Cap
As of the previous market close, Gilead Sciences, Inc. has a market cap of $146.96B, which represents its share price of $118.44 multiplied by its outstanding shares number of 1.24B. As a large-cap company, GILD's shareholders are generally exposed to less risk than shareholders of small and mid-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
GILD 119.79 +1.35(1.14%)
Will GILD be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for GILD based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for GILD
GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
GILD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say
Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates
Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?
Other News for GILD
Gilead price target raised to $145 from $127 at Truist
Gilead price target raised by $18 at Truist, here's why
Is GILD likely to continue higher? Crossed Above 20 Day Moving Average shows up after advancing 1.14%
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026
Nasdaq 100 Rebounds, Amazon Jumps 10% On Strong Earnings: What's Moving Markets Friday?